ClinicalTrials.gg
RecruitingNCT07005154Updated Sep 3, 2026

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

A Phase 2 interventional study of ASP5541 and Prednisone in Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer and Metastatic Hormone Sensitive Prostate Cancer, sponsored by Astellas Pharma Global Development, Inc.. Recruiting at 54 sites in 12 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 75 studies testing prednisone in Prostatic Neoplasms — 9 open to participants now, 17 under way, 1 of them phase 3. Prednisone · Prostatic Neoplasms.

Planned enrollment
15th of 73
218 · median 57
Started
2025
with 2 others
Phase 2
40 of 75
6 open now
Primary completion
2032-05
later than 14 of 16 live
Registered
72nd of 75
by date

Among the 75 studies testing prednisone in Prostatic Neoplasms, this one is the 15th largest by planned enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2025, is one of 40 in phase 2, reaches primary completion later than 14 of the 16 other live ones, and was the 72nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 75 studies testing prednisone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About prednisone

Prednisone: first FDA approval 1955 (METICORTEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies testing prednisone in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much testosterone is made or block testosterone from reaching the prostate cancer cells. Abiraterone acetate (AA) is an ARPI that is used to treat advanced prostate cancer. This type of treatment is usually given as a tablet with a steroid called prednisone/prednisolone to manage any medical problems from the hormone therapy.

ASP5541 is a different form of abiraterone acetate. It is given as an injection into the muscle. In this study, ASP5541 will be given to men with advanced prostate cancer, both with and without prednisone/prednisolone. This study will check the safety of ASP5541 and compare how well ASP5541 works in men with advanced prostate cancer compared to abiraterone acetate.

The main aims of the study are:

  • To check how well ASP5541 with prednisone/prednisolone works compared to AA with prednisone/prednisolone in men with advanced prostate cancer who haven't previously been treated with an ARPI.
  • To check the safety of ASP5541 given by itself in men with advanced prostate cancer that haven't previously been treated with an ARPI.
  • To check how well ASP5541 given by itself works compared to AA with prednisone/prednisolone in men with advanced prostate cancer that haven't previously been treated with an ARPI.
  • To check the safety of ASP5541 with prednisone/prednisolone in Japanese men with advanced prostate cancer.

Adult men with a certain type of advanced prostate cancer can take part. Their cancer has spread to other parts of the body (metastatic). The different types are:

  • Metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer that needs testosterone to grow.
  • Metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer that continues to grow even when testosterone levels are low.

In this study there will be 3 treatment groups:

  • In Group 1, men with mCRPC who haven't previously been treated with an androgen receptor pathway inhibitor will either be given ASP5541 and prednisone/prednisolone or be given abiraterone acetate and prednisone/prednisolone.
  • In Group 2, men with mHSPC who haven't previously been treated with an androgen receptor pathway inhibitor will either be given ASP5541 by itself or be given abiraterone acetate with prednisone/prednisolone.
  • In Group 3, Japanese men with mCRPC or mHSPC who may or may not have previously been treated with an androgen receptor pathway inhibitor will be given ASP5541 with prednisone/prednisolone.

ASP5541 will be given as an injection into a muscle every 12 weeks. Men with mCRPC will take prednisone/prednisolone twice daily and men with mHSPC will take prednisone/prednisolone once daily. Abiraterone acetate will be given as tablets to be taken once daily. All groups will also receive the standard of care treatment, such as androgen deprivation therapy.

The men in the study will visit their clinic regularly during and after treatment for health checks, including checking for any medical problems. Some men (Group 2) will check their blood pressure weekly at home. On some visits they will also have scans to check for any changes in their cancer. The number of visits and type of safety checks done at each visit will depend on the health of each person and when they completed their treatment.

03

Conditions studied

  • Prostate Cancer
  • Metastatic Castration-Resistant Prostate Cancer
  • Metastatic Hormone Sensitive Prostate Cancer

Browse trials for

Keywords

  • ASP5541
  • PRL-02
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is diagnosed with or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features.
  • Participant has performance status of 0 or 1, or ECOG performance status of 2 if due to bone pain.
  • Participant must have an estimated of ≥ 12 months with mHSPC or ≥ 6 months with mCRPC.
  • Participant is able to understand and comply with all study requirements and procedures.
  • Participant has been diagnosed with mCRPC or mHSPC documented by lesions on a bone scan, computed tomography (CT), magnetic resonance imaging (MRI) or prostate-specific membrane antigen positron emission tomography (PSMA-PET).
  • Participant is receiving ongoing ADT with a gonadotropin-releasing hormone (GnRH) analogue or has a history of bilateral orchiectomy (i.e., surgical or medical castration). Participant with mHSPC must have started castration therapy (medical or surgical) at least 14 days prior to Cycle 1 Day 1 (C1D1).

Note: Participant who has not had a bilateral orchiectomy must have a plan to maintain effective GnRH analogue therapy for the duration of the study.

  • If the participant has mCRPC, participant has evidence of disease progression defined as 1 or more of the following criteria at study entry:

    • Evidence of radiographic progression of disease prior to first dose and following the most recent prostate cancer treatment, defined as progressive disease on CT/MRI per (RECIST) v1.1 or on a bone scan per PCWG3.
    • PSA progression defined as an increase in PSA of at least 25% and ≥ 1 ng/mL above the nadir, confirmed by a second value 1 week later, and with at least 1 of the measurements within 90 days prior to screening. PSA nadir is defined as the lowest PSA during or after the most recent treatment.
  • If the participant has mCRPC, participant has a serum testosterone level \< 1.73 nmol/L (\< 50 ng/dL) at the Screening visit.
  • Male participant must agree to use with female partner(s) of (including breastfeeding partner) throughout the treatment period and for 7 months after final ASP5541 administration.
  • Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the period and for 7 months after final ASP5541 administration.
  • Male participant must not donate sperm during the treatment period and for 7 months after final ASP5541 administration.
  • Participant agrees not to participate in another interventional study while receiving ASP5541 in the present study.
  • Participant should have normal serum potassium (within the local laboratory normal range) at screening without supplementation.

Exclusion criteria

Exclusion Criteria:

  • Participant has any concurrent disease, infection or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.
  • Participant has known active central nervous system (CNS) . Note: Participant with who has been treated with surgery and/or radiation therapy, who is off pharmacologic doses of and who is neurologically stable is eligible.
  • Participant has a known additional beyond prostate cancer that requires active treatment with the exception of any of the following:

    • Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ carcinoma of any type
    • Adequately treated Stage I cancer from which the participant is currently in remission and has been in remission for ≥ 2 years
    • Any other cancer from which the participant has been disease-free for ≥5 years
  • Participant has cardiac disease, defined as any of the following:

    • Clinically significant cardiac arrhythmias including bradyarrhythmia which are poorly controlled. Rate-controlled atrial fibrillation is permitted.
    • Congenital long syndrome.
    • QT interval corrected by Fridericia's formula (QTcF) ≥450 msec at Screening. If the QT interval corrected for heart rate intervals (QTc) is prolonged in a participant with a pacemaker or bundle branch block, the participant may be enrolled in the study if confirmed by the medical monitor.
    • History of clinically significant cardiac disease or congestive heart failure greater than (NYHA) Class II or measurement of \< 50% at baseline.
    • Cohorts 1 and 3: Participant must not have unstable angina (symptoms at rest) or new-onset angina within the last 3 months or myocardial infarction within the past 6 months.
    • Cohort 2: Participants must not have symptomatic heart failure, unstable or new-onset angina or myocardial infarction within the past 12 months.
    • Cohorts 1 and 3: Uncontrolled hypertension, defined as systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg that has been confirmed by 2 successive measurements despite optimal medical management.
    • Cohort 2: Uncontrolled hypertension, defined as systolic BP > 140 mmHg or diastolic BP > 90 mmHg that has been confirmed by 2 successive measurements despite optimal medical management. Participants may be receiving a maximum of 2 antihypertensives that were initiated at least 3 months prior to Cycle 1 Day 1.
    • Cohort 1 and 3: Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis, or pulmonary embolism within the 3 months before start of study medication (except for adequately treated catheter related venous thrombosis occurring > 1 month before Cycle 1 Day 1).
    • Cohort 2: Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks) within the last 12 months.
  • Participant has any unresolved National Cancer Institute- (NCI-CTCAE) (version 5.0) Grade > 2 toxicity at the Screening visit. Note: Participant receiving ongoing hormone replacement therapy for endocrine immune-related AEs without clinical symptoms will not be excluded.
  • Participant has had major surgery (e.g., requiring general anesthesia) within 30 days before screening, or has not fully recovered from surgery, or has major surgery planned during the time the participant is expected to participate in the study.
  • Participant has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 28 days prior to day 1.
  • Participant received a blood transfusion within 1 month of the first dose of study intervention.
  • Participant has a history of impaired pituitary or adrenal gland function (e.g., Addison's disease, Cushing's syndrome).
  • Participant has (HbA1c) > 10% (if diabetes mellitus was previously diagnosed) or HbA1c > 8% (if diabetes mellitus was previously undiagnosed). (Excluded participant may be rescreened after referral and evidence of improved control of their condition.)
  • Participant has jaundice or known current active liver disease from any cause, including hepatitis A (hepatitis A virus IgM positive, but testing for hepatitis A in screening is not required), (hepatitis B virus surface antigen positive, confirmed by hepatitis B virus DNA), or (hepatitis C virus antibody positive, confirmed by hepatitis C virus RNA).
  • Participant has moderate or severe hepatic impairment ( Class B or C).
  • Participant has a known history of (HIV) infection (HIV antibody positive).
  • Participant has a > 40 kg/m2.
  • Participant has a history of drug or alcohol abuse according to , 5th edition criteria within 2 years before screening.
  • Participant received treatment with glucocorticoids greater than the equivalent of 10 mg per day of prednisone within 4 weeks prior to C1D1. The use of topical, intraocular, inhalational, intranasal or intra-articular glucocorticoids is permitted.
  • Participant received treatment with herbal medications with known anti-cancer properties or known effects on prostate physiology within 4 weeks prior to Cycle 1 Day 1 (e.g., saw palmetto, St. John's wort, turmeric/curcumin). Participants must agree not to use herbal products during study participation.
  • Participant is receiving current treatment with systemic ketoconazole, abiraterone acetate (AA) or any other cytochrome P450 17A1 (CYP17) inhibitor. Participant who has received systemic ketoconazole, AA or any other CYP17 inhibitor must have discontinued these agents ≥ 4 weeks prior to the first dose of study intervention.
  • Participant received prior systemic treatment with a strong inducer or inhibitor of cytochrome p450 3A4 () within 4 weeks of first dose of study intervention. Concomitant use of strong inducers or inhibitors of CYP3A4 are not permitted on study.
  • Participant requires use of biotin (i.e., vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 μg. Note: Participant who switches from a high dose to a dose of 30 μg/day or less prior to first dose of study drug is eligible for study entry.
  • Participant is required to use any prohibited medication on the List of Excluded Concomitant Medications.
  • For mCRPC participants only: Participant has been treated with any of the following for prostate cancer, during the indicated time frame prior to enrollment:

    • Hormonal therapy (e.g., androgen receptor blockers [AR] antagonists, second-generation androgen receptor pathway inhibitors [including enzalutamide, apalutamide, darolutamide, rezvilutamide and AA], 5-alpha reductase inhibitors, estrogens, cyproterone acetate) within 4 weeks of C1D1. Note: Participant has been treated with bicalutamide within 6 weeks prior to enrollment is not permitted. Participant has been treated with all other GnRH analogues or antagonists is permitted.
    • Chemotherapy within 2 weeks or 5 half-lives of C1D1 (whichever is longer)
    • Biologic therapy within 4 weeks of C1D1
    • Immunotherapy within 4 weeks of C1D1
    • Radiation therapy (includes radioligands) within 4 weeks of C1D1
  • For mHSPC participants only: Participant has received any prior pharmacotherapy, radiation therapy or surgery for metastatic prostate cancer (the following exceptions are permitted):

    • Up to 4 months of ADT with GnRH agonists or antagonists or orchiectomy (within 3 months prior to C1D1) with or without concurrent antiandrogens.
    • Participant may have 1 course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 4 weeks prior to C1D1.
    • Up to 6 cycles of docetaxel therapy, with the last dose of docetaxel ≤ 2 months prior to C1D1. A participant who has received docetaxel should have maintained a response to docetaxel of stable disease or better, by imaging and PSA, prior to C1D1.
    • Up to 6 months of ADT with GnRH agonists or antagonists or orchiectomy with or without concurrent antiandrogens prior to C1D1 if subject was treated with docetaxel, with no radiographic evidence of disease progression or rising PSA levels prior to C1D1.
  • Participant has received any therapy within 4 weeks or 5 half-lives (whichever is longer) prior to C1D1.
  • Participant has received ASP5541 previously.
  • Participant has \< 1500/μL, count \< 100000/μL or \< 9 g/dL (6.2 mmol/L) or (INR) ≥ 1.5 (unless participant is taking oral anticoagulants in which case INR ≤ 2.0 is permitted) at Screening. Note: Participant may not have received any growth factors within 7 days or blood transfusions within 28 days prior to the hematology values obtained at Screening.
  • Participant has serum total > 1.5 x (ULN) (or > 3 x ULN for participants with documented Gilbert's disease), or serum or aspartate aminotransferase > 2.5 x ULN at Screening.
  • Participant does not have adequate renal function defined as a calculated \< 30 mL/min as determined by a validated algorithm for calculating creatinine clearance.
  • Participant has serum albumin \< 3.0 g/dL (30 g/L) at Screening.
  • Participant has a known or suspected to ASP5541, prednisone, or any components of the formulations used.
  • Participant has a gastrointestinal disorder affecting absorption.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
218 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (mCRPC) Group A

    Participants will receive ASP5541 every 12 weeks + prednisone/prednisolone twice daily

    Drug: ASP5541 · Drug: Prednisone · Drug: Prednisolone · Drug: Adrenocorticotropic hormone

  • Active comparator
    Cohort 1 (mCRPC) Group B

    Participants will receive abiraterone acetate once daily + prednisone/prednisolone twice daily

    Drug: Prednisone · Drug: Prednisolone · Drug: abiraterone acetate · Drug: Adrenocorticotropic hormone

  • Experimental
    Cohort 2 (mHSPC) Group A (Safety Run In)

    Participants will receive ASP5541 every 12 weeks

    Drug: ASP5541 · Drug: Adrenocorticotropic hormone

  • Experimental
    Cohort 2 (mHSPC) Group B

    Participants will receive ASP5541 every 12 weeks

    Drug: ASP5541 · Drug: Adrenocorticotropic hormone

  • Active comparator
    Cohort 2 (mHSPC) Group C

    Participants will receive abiraterone acetate once daily + prednisone/prednisolone once daily

    Drug: Prednisone · Drug: Prednisolone · Drug: abiraterone acetate · Drug: Adrenocorticotropic hormone

  • Experimental
    Cohort 3 (mCRPC or mHSPC) Japanese Participants Only

    Participants will receive ASP5541 every 12 weeks + prednisone/prednisolone twice daily (for mCRPC) or prednisone/prednisolone once daily (for mHSPC)

    Drug: ASP5541 · Drug: Prednisone · Drug: Prednisolone · Drug: Adrenocorticotropic hormone

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of androgen receptor pathway inhibitor (ARPI) -naïve metastatic castration-resistant prostate cancer (mCRPC) participants with Prostate Specific Antigen (PSA) decline ≥ 90% (Cohort 1)

    PSA will be recorded from blood sample.

    Time frame: Up to 37 months

  2. Rate of no mineralocorticoid toxicity (Cohort 2 Group A, Safety run-in)

    No mineralocorticoid toxicity is defined as experiencing neither Grade ≥ 1 hypokalemia nor Grade ≥ 2 hypertension.

    Time frame: Up to 37 months

  3. Proportion of metastatic hormone-sensitive prostate cancer (mHSPC) participants with prostate-specific antigen (PSA) ≤ 0.2 ng/mL (Cohort 2)

    PSA will be recorded from blood sample.

    Time frame: At 8 months

  4. Dose-limiting toxicities (DLTs) (Cohort 3)

    A DLT is defined as any event meeting the DLT criteria occurring during the first 28 days of treatment regardless of attribution to the study drug unless it is clearly related to disease progress or intercurrent illness.

    Time frame: Up to Day 28

  5. Number of participants with Adverse Events (AEs) (Cohort 3)

    AEs will be coded using MedDRA. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 39 months

  6. Number of Participants With Serious Adverse Events (SAEs) (Cohort 3)

    An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is congenital anomaly/birth defect or other situations.

    Time frame: Up to 39 months

  7. Number of participants with laboratory value abnormalities and/or AEs (Cohort 3)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to 37 months

  8. Number of participants with electrocardiogram (ECG) abnormalities and/or AEs (Cohort 3)

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to 36 months

  9. Number of participants with vital sign abnormalities and/or AEs (Cohort 3)

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to 37 months

  10. Number of participants with physical exam abnormalities and/or AEs (Cohort 3)

    Number of participants with potentially clinically significant physical exam values.

    Time frame: Up to 36 months

  11. Eastern Cooperative Oncology Group (ECOG) Performance Status (Cohort 3)

    The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

    Time frame: Up to 36 months

Secondary outcomes

  1. Radiographic progression-free survival (rPFS)

    Radiographic progression-free survival (rPFS) is defined as the time from the date of randomization/first dose date until the date of radiological progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and Prostate Cancer Working Group 3 (PCWG3) as determined by investigator or death from any cause.

    Time frame: Up to 84 months

  2. Prostate-specific antigen (PSA) decline ≥ 50% from baseline

    Proportion of participants who had a PSA decline of ≥ 50% from baseline, confirmed by a second consecutive PSA assessment at least 3 weeks later.

    Time frame: Up to 37 months

  3. PSA decline ≥ 90% (Cohorts 2 & 3 only)

    Proportion of participants who had a PSA decline of ≥ 90% from baseline, confirmed by a second consecutive PSA assessment at least 3 weeks later.

    Time frame: Up to 37 months

  4. PSA undetectable rate (≤ 0.2 ng/mL) (Cohorts 1 & 3)

    Proportion of participants achieving a PSA level ≤ 0.2 ng/mL at any time post baseline.

    Time frame: Up to 37 months

  5. PSA undetectable rate (≤ 0.02 ng/mL)

    Proportion of participants achieving a PSA level ≤ 0.02 ng/mL at any time post baseline.

    Time frame: Up to 37 months

  6. Time to PSA progression per PCWG3 criteria

    Time from first dose date to the date of the first PSA value demonstrating a ≥ 25% increase and an absolute increase of ≤ 0.2 ng/mL above the nadir (i.e., the lowest PSA value observed post baseline or at baseline), which is confirmed by a second consecutive value at least 3 weeks later.

    Time frame: Up to 37 months

  7. Objective response rate (ORR)

    Proportion of participants who achieved a confirmed Complete Response (CR) or Partial Response (PR) in their soft tissue disease using RECIST v1.1 criteria and PCWG3 for bone disease.

    Time frame: Up to 84 months

  8. Duration of response (DOR)

    Time from first date of confirmed CR or confirmed PR until the date of radiological PD per RECIST v1.1 and PCWG3 as determined by investigator or death from any cause.

    Time frame: Up to 84 months

  9. Best overall response (BOR)

    The best response derived from all time points' overall responses (CR, PR, stable disease or non-CR/non-PD \[for participants with no measurable disease at baseline\], PD, not evaluable and not determined in order).

    Time frame: Up to 84 months

  10. Number of participants with Adverse Events (AEs) (Cohorts 1 & 2)

    AEs will be coded using MedDRA. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 39 months

  11. Number of Participants With Serious Adverse Events (SAEs) (Cohorts 1 & 2)

    An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity is congenital anomaly/birth defect or other situations.

    Time frame: Up to 39 months

  12. Number of participants with laboratory value abnormalities and/or AEs (Cohorts 1 & 2)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to 37 months

  13. Urine potassium (Cohort 2)

    Potassium level will be recorded from urine sample.

    Time frame: Up to 37 months

  14. Urine creatinine (Cohort 2)

    Creatinine level will be recorded from urine sample.

    Time frame: Up to 37 months

  15. Number of participants with electrocardiogram (ECG) abnormalities and/or AEs (Cohorts 1 & 2)

    Number of participants with potentially clinically significant ECG values/cardiac monitoring.

    Time frame: Up to 36 months

  16. Number of participants with vital sign abnormalities and/or AEs (Cohorts 1 & 2)

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to 37 months

  17. Number of participants with physical exam abnormalities and/or AEs (Cohorts 1 & 2)

    Number of participants with potentially clinically significant physical exam values.

    Time frame: Up to 36 months

  18. ECOG Performance Status (Cohort 1 & 2 only)

    The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

    Time frame: Up to 36 months

  19. Number of participants with testosterone suppression to ≤ 1 ng/dL, or achieves a ≥ 90% reduction from baseline

    Testosterone value will be recorded from blood sample.

    Time frame: Up to 37 months

  20. Mean testosterone value by timepoint

    Testosterone value will be recorded from blood sample.

    Time frame: Up to 37 months

  21. Median time to testosterone suppression of levels ≤ 1 ng/dL

    Time to testosterone suppression is defined as time from date of randomization/first dose date until testosterone suppression to ≤ 1 ng/mL.

    Time frame: Up to 37 months

  22. Time to pain progression

    Time to pain progression defined using pain scores from the Brief Pain Inventory - Short form (BPI-SF) and opiate analgesic use will be evaluated.

    Time frame: Up to 36 months

07

Study locations

54 of 54 sites recruiting
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
    Recruiting
  • Sharp HealthCare - Sharp Memorial Hospital
    San Diego, California 92123, United States
    Recruiting
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
  • Associated Urological Specialists
    Chicago Ridge, Illinois 60415, United States
    Recruiting
  • NorthShore University HealthSystem
    Evanston, Illinois 60201, United States
    Recruiting
  • Ochsner Health - Ochsner Medical Center - New Orleans
    New Orleans, Louisiana 70121, United States
    Recruiting
  • New Mexico Oncology Hematology Consultants
    Albuquerque, New Mexico 87109, United States
    Recruiting
  • Solaris Health - The Urology Group
    Cincinnati, Ohio 45212, United States
    Recruiting
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
  • Tennessee Oncology Nashville
    Nashville, Tennessee 37203, United States
    Recruiting
  • University of Virginia Cancer Center
    Charlottesville, Virginia 22908-07, United States
    Recruiting
  • UW Health Carbone Cancer Center
    Madison, Wisconsin 53792, United States
    Recruiting
  • Subei People's Hospital
    Yangzhou, Jiangsu 225001, China
    Recruiting
  • The Second Hospital of Tianjin Medical University
    Tianjin, Tianjin Municipality 300211, China
    Recruiting
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
  • Huai'an First People's Hospital
    Huaian, 211731, China
    Recruiting
  • Renji Hospital Shanghai Jiaotong Univ School of Medicine
    Shanghai, 200127, China
    Recruiting
  • Site FR33003
    Bordeaux, France
    Recruiting
  • Site FR33009
    Le Mans, France
    Recruiting
  • Site FR33008
    Lille, France
    Recruiting
  • Site FR33006
    Paris, France
    Recruiting
  • Site FR33004
    Strasbourg, France
    Recruiting
  • Site DE49004
    Nürtingen, Baden-Wurttemberg, Germany
    Recruiting
  • Site DE49001
    Heinsberg, Germany
    Recruiting
  • Site IT39004
    Milan, Italy
    Recruiting
  • Site IT39006
    Milan, Italy
    Recruiting
  • Site IT39005
    Roma, Italy
    Recruiting
  • Site IT39003
    Trento, Italy
    Recruiting
  • National Cancer Center Hospital East
    Kashiwa, Chiba, Japan
    Recruiting
  • Shizuoka Cancer Center
    Sunto-gun, Shizuoka, Japan
    Recruiting
  • Nippon Medical School Hospital
    Bunkyo-ku, Tokyo, Japan
    Recruiting
  • The Cancer Institute Hospital of JFCR
    Koto, Tokyo, Japan
    Recruiting
  • Harasanshin Hospital
    Fukuoka, Japan
    Recruiting
  • Osaka International Cancer Institute
    Osaka, Japan
    Recruiting
  • Site PL48003
    Gdansk, Poland
    Recruiting
  • Site PL48007
    Gliwice, Poland
    Recruiting
  • Site PL48005
    Mysłowice, Poland
    Recruiting
  • Site PL48008
    Otwock, Poland
    Recruiting
  • PanOncology Trials
    San Juan, Puerto Rico
    Recruiting
  • Site KR82006
    Daegu, South Korea
    Recruiting
  • Site KR82008
    Gwangju, South Korea
    Recruiting
  • Site KR82002
    Seoul, South Korea
    Recruiting
  • Site KR82003
    Seoul, South Korea
    Recruiting
  • Site KR82004
    Seoul, South Korea
    Recruiting
  • Site KR82007
    Seoul, South Korea
    Recruiting
  • Site ES34006
    Barcelona, Catalonia, Spain
    Recruiting
  • Site ES34005
    Barcelona, Spain
    Recruiting
  • Site ES34008
    Barcelona, Spain
    Recruiting
  • Site ES34001
    Madrid, Spain
    Recruiting
  • Site ES34003
    Santiago de Compostela, Spain
    Recruiting
  • Site TW88603
    Kaohsiung City, Taiwan
    Recruiting
  • Site TW88604
    Taichung, Taiwan
    Recruiting
  • Site TW88602
    Taipei, Taiwan
    Recruiting
  • Site GB44003
    London, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for May 2032, 81 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 81 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 5, 2025
StartActual
Aug 19, 2025
Primary completionEst.
May 31, 2032
CompletionEst.
May 31, 2032
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07005154
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Aug 19, 2025
Primary completion
May 31, 2032 (estimated)
Completion
May 31, 2032 (estimated)
Last update
Sep 3, 2026

Study contacts

Astellas Pharma Global Development, Inc.
Contact
Astellas.registration@astellas.com
800-888-7704
Medical Monitor
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Prednisone · Prednisolone

Start the discussion